Nabi Biopharmaceuticals (NABI) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss) from continuing operations	-10M
Depreciation and amortization
Accretion of discount on convertible senior notes
Share-based compensation	400K
Loss (gain) on sale of property and equipment
Receivables
Prepaid expenses and other assets	-1.2M
Accounts payable, accrued expenses and other liabilities
Deferred revenue
Net cash provided by (used in) operating activities from continuing operations	-10.7M
Net cash used in operating activities from discontinued operations
Net cash provided by (used in) operating activities
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Proceeds from sales of property and equipment
Capital expenditures
Net cash provided by (used in) investing activities
Proceeds from issuances of common stock for employee benefit plans
Purchase of common stock for treasury
Repurchase of convertible senior notes
Net cash provided by (used in) financing activities
Net increase (decrease) in cash and cash equivalents	-3.8M
Cash and cash equivalents at beginning of period	49.7M
Cash and cash equivalents at end of period	45.9M

Entities mentioned with NABI

View All Entities